Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis

Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis

Submitted by admin on January 26, 2024 - 11:19am
Source: 
BioSpace
News Tags: 
Regeneron
Sanofi
Dupixent
eosinic esophagitis
pediatric
FDA
Headline: 
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
snippet: 

The FDA on Thursday approved the use of Regeneron and Sanofi’s blockbuster therapy Dupixent (dupilumab) for the treatment of eosinic esophagitis in children aged 1 to 11 years.

Do Not Allow Advertisers to Use My Personal information